Cysteine mutated antibodies for conjugation
US11938194B2 · kind B2 · utility
0Cited by
26References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 28, 2018 |
| Grant date | Mar 26, 2024 |
| Priority date | — |
| Expiry date | Nov 22, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/524
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.